Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFR64 T cells plus anti-CD20 monoclonal antibody in relapsed/refractory B-cell lymphoma
ChiCTR2200060343Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- May 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CFR64 T in mature B-cell lymphoma and B-cell malignancy, sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Safety. Started May 2022; status: recruiting.
02
Drugs
CFR64 T
03
Conditions
mature B-cell lymphomaB-cell malignancy
Beyond the preview
Go deeper on ChiCTR2200060343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060343.